思創醫惠(300078.SZ):人工智能、區塊鏈技術與醫療場景融合的其他產品正在積極開發中
格隆匯5月23日丨思創醫惠(300078.SZ)在5月23日15:00-17:00業績説明會表示,近年來,公司在大數據、人工智能應用方面持續進行研發投入,具體如下:1、在自然語言處理的應用方面,公司在單病種、基層衞生等業務場景中積極應用人工智能輔助決策支持,能夠自動從電子病歷文書中抓取診斷、症狀、部位等相關信息,與核心指標的關聯,生成相關報吿。2、利用人工智能技術應用到膿毒血癥的預警平台,幫助醫生在急診過程中能夠及時尋找到危重病人,提升醫生在工作中處理突發事件的能力。3、人工智能、區塊鏈技術與醫療場景融合的其他產品正在積極開發中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.